{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:24:27Z","timestamp":1791955467305,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.lungcan.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T21:11:02Z","timestamp":1554844262000},"page":"126-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"132","author":[{"given":"Keunchil","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Moro","family":"Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Huat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-5138","authenticated-orcid":false,"given":"James C.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"M\u00e4rten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.04.014_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0010","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0020","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.04.014_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2217\/fon-2017-0636","article-title":"Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?","volume":"14","author":"Girard","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 8","key":"10.1016\/j.lungcan.2019.04.014_bib0040","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0045","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-018-0612-z","article-title":"Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib","volume":"14","author":"Hochmair","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0060","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0065","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.31891","article-title":"Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies","volume":"125","author":"Ahn","year":"2019","journal-title":"Cancer"},{"issue":"27","key":"10.1016\/j.lungcan.2019.04.014_bib0070","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2217\/fon-2018-0711","article-title":"Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study","volume":"14","author":"Hochmair","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2019.04.014_bib0075","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2018-0736","article-title":"Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing","volume":"15","author":"Kohsaka","year":"2019","journal-title":"Future Oncol."},{"issue":"Suppl. 8","key":"10.1016\/j.lungcan.2019.04.014_bib0080","first-page":"viii493","article-title":"Which is better EGFR-TKI followed by osimertinib between afatinib and gefitinib\/erlotinib?","volume":"29","author":"Tamiya","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219304015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219304015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:29:47Z","timestamp":1759235387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219304015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"alternative-id":["S0169500219304015"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}